{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:16:44Z","timestamp":1761743804089},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T00:00:00Z","timestamp":1407283200000},"content-version":"vor","delay-in-days":339,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jcv.2013.06.035","type":"journal-article","created":{"date-parts":[[2013,7,20]],"date-time":"2013-07-20T13:45:19Z","timestamp":1374327919000},"page":"67-73","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective"],"prefix":"10.1016","volume":"58","author":[{"given":"D.J.W.","family":"Wesdorp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Knoester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.E.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Coenraad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.T.M.","family":"Vossen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.C.J.","family":"Claas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"van Hoek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2013.06.035_bib0005","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1053\/jhep.2002.33681","article-title":"Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease","volume":"35","author":"Steinmuller","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0010","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/lt.20217","article-title":"Outcome of liver transplantation for hepatitis B in the United States","volume":"10","author":"Kim","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jcv.2013.06.035_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2559.1993.tb01179.x","article-title":"Recurrent hepatitis B in liver allografts: a distinctive form of rapidly developing cirrhosis","volume":"23","author":"Harrison","year":"1993","journal-title":"Histopathology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0020","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00007890-199104000-00011","article-title":"Serologic and DNA follow-up data from HBsAg-positive patients treated with orthotopic liver transplantation","volume":"51","author":"Freeman","year":"1991","journal-title":"Transplantation"},{"key":"10.1016\/j.jcv.2013.06.035_bib0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0168-8278(92)90138-F","article-title":"Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications","volume":"14","author":"O\u2019Grady","year":"1992","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2013.06.035_bib0030","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(91)92515-4","article-title":"Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients","volume":"337","author":"Samuel","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2013.06.035_bib0035","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen","volume":"329","author":"Samuel","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2013.06.035_bib0040","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(96)04444-3","article-title":"Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis","volume":"348","author":"Grellier","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2013.06.035_bib0045","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jlts.2000.8310","article-title":"Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B","volume":"6","author":"Angus","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jcv.2013.06.035_bib0050","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1002\/lt.20258","article-title":"Evolving strategies to prevent HBV recurrence","volume":"10","author":"Roche","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jcv.2013.06.035_bib0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"Management of chronic hepatitis B virus infection","volume":"57","author":"EASL clinical practice guidelines","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2013.06.035_bib0060","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.transproceed.2012.06.019","article-title":"Telbivudin as prophylaxis for hepatitis B virus recurrence after liver transplantation: a case series in single-center experience","volume":"44","author":"Perrella","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jcv.2013.06.035_bib0065","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00007890-199702150-00027","article-title":"Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation","volume":"63","author":"Burbach","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.jcv.2013.06.035_bib0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1432-2277.2011.01222.x","article-title":"Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study","volume":"24","author":"Yahyazadeh","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.jcv.2013.06.035_bib0075","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22524","article-title":"A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis","volume":"48","author":"Angus","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0080","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1399-0012.2005.00467.x","article-title":"prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy","volume":"20","author":"Nath","year":"2006","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jcv.2013.06.035_bib0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1600-6143.2010.03416.x","article-title":"Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy","volume":"11","author":"Saab","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jcv.2013.06.035_bib0090","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0095","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2007.12.026","article-title":"Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B","volume":"48","author":"Sung","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2013.06.035_bib0100","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0105","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","article-title":"Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial","volume":"47","author":"Hou","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0110","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"129","author":"Lai","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0115","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2013.06.035_bib0120","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0125","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/j.gastro.2011.06.083","article-title":"Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation","volume":"141","author":"Fung","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0130","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1053\/j.gastro.2011.09.052","article-title":"Combined prophylaxis might still be better than monoprophylaxis with entecavir following liver transplantation for hepatitis B","volume":"142","author":"Samuel","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0135","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0140","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1478-3231.2012.02770.x","article-title":"Substitution of tenofovir\/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation","volume":"32","author":"Stravitz","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jcv.2013.06.035_bib0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0150","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0168-8278(10)60030-X","article-title":"Emtricitabine-tenofovir DF combination\u00b1HBIG post\/orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results","volume":"52","author":"Teperman","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2013.06.035_bib0155","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"48","author":"Marcellin","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2013.06.035_bib0160","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/gut.2005.077099","article-title":"Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil","volume":"55","author":"Yeon","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jcv.2013.06.035_bib0165","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2007.12.024","article-title":"Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response","volume":"48","author":"Baldick","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2013.06.035_bib0170","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1872-034X.2012.01020.x","article-title":"Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation","volume":"43","author":"Ueda","year":"2013","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jcv.2013.06.035_bib0175","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1399-0012.2011.01448.x","article-title":"Clinical study on prevention of HBV re-infection by entecavir after liver transplantation","volume":"26","author":"Cai","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jcv.2013.06.035_bib0180","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1399-3062.2012.00741.x","article-title":"Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation","volume":"14","author":"Cholongitas","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcv.2013.06.035_bib0185","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-6143.2012.04315.x","article-title":"High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B Virus recurrence after liver transplantation: a systematic review","volume":"13","author":"Cholongitas","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jcv.2013.06.035_bib0190","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653213002679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653213002679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T12:24:49Z","timestamp":1539519889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653213002679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1386653213002679"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2013.06.035","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2013.06.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}